Generic Name and Formulations:
Dutasteride 0.5mg; caps.
Indications for AVODART:
BPH, as monotherapy to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery; or in combination with tamsulosin. Limitation of use: not approved for preventing prostate cancer.
Swallow whole. Monotherapy: 0.5mg once daily. Combination therapy: 0.5mg once daily with tamsulosin 0.4mg once daily.
Not for use in children or women. Pregnant women and those of childbearing potential should avoid handling caps.
Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values (establish new baseline PSA after at least 3months of treatment); double PSA levels to compare with normal values. Rule out prostate cancer and other urological disorders prior to treatment. Hepatic dysfunction. Avoid donating blood until at least 6months after last dose.
Type I and II 5 alpha-reductase inhibitor.
May be potentiated by CYP3A4/5 inhibitors (eg, ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, ciprofloxacin); caution.
Impotence, decreased libido, ejaculation disorder, gynecomastia, dizziness (with tamsulosin).
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners